Ribociclib Nitroso Impurity 2

It is one of impurity present in Ribociclib, Ribociclib is a selective cyclin-dependent kinase inhibitor by inhibiting two proteins called cyclin-dependent kinase. Inhibition of cyclin-dependent kinase 4 and 6 protect oncogenic processes in specific tissue type. CDK4 is needed for the growth of Ras-induced mammary tumors, suggesting a potential therapeutic window for treatment with lower toxicity. Ribociclib is a selective CDK4/6 inhibitor and has dose-dependent antitumor activity in several preclinical models. It inhibited the growth of tumor cells by arresting the cells at the G1 checkpoint, which prevents the tumor cells from proliferating, also used to treat HR+ and metastatic breast cancer.

Additional information

Catalogue No.

VE0010063

CAS No.

N/A

Molecular Formula

C23H28N10O3

Molecular Weight

492.5 g/mol

Status

In-stock

References

Bartsch, R. (2017). Ribociclib: a valuable addition to treatment options in breast cancer? ESMO Open, 2(3), e000246. https://doi.org/10.1136/esmoopen-2017-000246